（旧版）「喘息ガイドライン作成に関する研究」平成11年度研究報告書/ガイドライン引用文献(2000年まで)簡易版抄録を掲載

6.文献リスト

1. Lal S, Borow PD, Venho KK, et al: Nedcromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993; 104:438-447. (評価 II,A)
2. Furukawa C, Atkinson D, Foster TJ, et al: Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients > or = 12 years of age. Intal Study Group. Chest 1999;116:65-72. (評価 II,A)
3. Medici TC, Radielovic P, Morley J, et al: Ketotifen in the prophlaxis of extrinsic bronchial asthma. A multicenter controlled double-blind study with a modified- release formulation. Chest 1989; 96:1252-1257. (評価 II,B)
4. Shimoda M, Nakamura Y, Shin Z, et al: Effect of ketotifen on symptoms and on bronchial mucosa in patiemts with atopic asthma. Allergy 1997; 52:814-820. (評価 II,A)
5. Hoshino M, Nakamura Y, Sim JJ, et al: A comparative study of the effect of ketotifen, disodium cromoglycate and beclomethsone dipropionate on bronchial mucosa and asthma symptom in patients with atopic asthma. Respiratory Medicine 1998; 92:942-950. (評価 II,A)
6. Azelastine-Asthma Study Group: An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J Allergy Clin Immunol 1996; 97:1218-1224. (評価 II,A)
7. Busse WW, Middleton E, Storms W, et al: Corticosteroid-sapring effect of azelastine in the management of bronchial astham. Am J Respir Crit Care Med 1996; 153:122-127. (評価 II,A)
8. Hoshino M, Nakamura Y: The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997;114: 285-292. (評価 II,B)
9. Hoshino M, Sim J, Shimizu K, et al: Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. J Allergy Clin Immunol 1999; 103: 1054-1061. (評価 II,B)
10. Yoshida S, Ishizaki Y, Shoji T, et al: Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy 2000; 30 : 1008-1014. (評価 II-2,A)
11. Barnes NC, Pujet JC, on behalf of an International Study Group: Pranlukast, a novel leukotriene receptor antagonist: results of the first European, プラセボ controllede, multicentre clinical study in asthma. Thorax 1997; 52:523-527. (評価 II,A)
12. Grossman J, Faiferman I, Dubb JW, et al: Results of the first U.S. double blind, プラセボ-controlled, multicenter clinical study in asthma with Pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34:321-328. (評価 II,B)
13. Spector SL, Smith Lj, Glasss M: Effect of 6 weeks of therapy with oral doses of ICI 204,219,a leukotoriene D4 receptor antagonist, in subjects with bronchial asthma. ACCORATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-623. (評価 II,A)
14. Fish JE, Kemp JP, Lockey RF, et al: Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialist Group. Clin Ther 1997;19:675-690. (評価 II,A)
15. Virchow JC Jr, Prasse A, Naya I, et al: Zafirkast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578-585. (評価 II,A)
16. Hamilton A, Faiferman I, Stober P, et al: Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuate allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998; 102:177-183. (評価 II-2,A)
17. Hamilton AL, Watson RM, Wyile G, et al: Attenuation of early amd late phase allergen-induced bronnchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997; 52:348-354. (評価 II-2,A)
18. Finnerty JP, Wood-Baker R, Thomson H, et al: Role of leukotrienes in exercise-induced asthma. Inihibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992;145:746-749. (評価 II-2,A)
19. Fujimura M, Sakamoto S, Kamio Y, et al: Effect of a leukotriene antagonist, ONO-1078,on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87:133-138. (評価 II-2,B)
20. Tamaoki J, Kondo M, Sakai N, et al: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235-1240. (評価 I,A)
21. Myou M, Fujimura M, Nishi K, et al: . Inhibitory effect of terfenadine, a selective H1-histamine receptor antagonist, on alchol beverage-induced bronchoconstriction in asthmatic patients. Eur Respir J 1995; 8:619-623. (評価 II,B)
22. Yamamoto H, Nagata M, Kuramitsu K: Inhibition of anlgegic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254-257. (評価 II,B)
23. Yoshida S, Sakamoto H, Ishizaki Y, et al: Effect of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersennsitivity toanalgegic in aspirin-intolerant asthma. Clin Exp Allergy 2000; 30 : 60-74. (評価 II-2,B)